On November 28, 2012, FDA approved a labeling change for the
Hepsera (adefovir dipivoxil) package insert to include the following
information under Section 5.5, Coadministration with Other Products, and to Section 17.1, Patient Counseling Information/Instructions for Safe Use.
- Hepsera should not be used concurrently with Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disporoxil fumarate combination tablet).
Hepsera is nucleotide analogue for the treatment of chronic hepatitis B infection, manufactured by Gilead Sciences.
The complete, up-to-date Hepsera label may be viewed at Drugs@FDA .
Richard Klein
Office of Special Health Issues
Food and Drug Administration
Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration
No hay comentarios:
Publicar un comentario